Esized that mortality in REVIVE could be comparable to ADHERE in all CARTdefined danger subgroups. Solutions REVIVE (n = 700) mortality data have been mapped making use of precisely the same variables/cut-points as the ADHERE CART evaluation. Final results Compared with ADHERE, proportionately far more patients in REVIVE had SBP <115 mmHg (56.4 vs 18.6 ; P < 0.001) with more patients (3.0 vs 1.9 ; P < 0.05) in the highest mortality risk subgroup (SBP <115 mmHg, BUN 43 mg/dl, and Cr 2.75 mg/dl). For the total population and for every CART-defined subgroup, REVIVE inhospital mortality rates were lower than those from ADHERE. See Figure 1.SCritical CareMarch 2007 Vol 11 Suppl27th International Symposium on Intensive Care and Emergency MedicineFigure 1 (abstract P223)Figure 1 (abstract P224)Mortality rates from REVIVE for subgroups defined by the ADHERE classification and regression tree model.Conclusion Clinical trials (REVIVE) may enroll proportionately more patients at increased risk of mortality in comparison with the general population (ADHERE). Despite the predicted increased mortality risk, mortality rates were lower in REVIVE than in ADHERE for the total population and for every CART-defined risk subgroup. Differences in SOC or additional risk factors, such as age or other comorbid conditions, may contribute to the poorer prognosis in nontrial populations.different mechanism of action. Catecholamines increase Ca2+ availability and LS increases myocardial cell calcium sensibility.P225 Retrospective study of proarrhythmic effects of levosimendan during the therapy of heart failureE Zima, G Szucs, A Soltesz, D Becker, G Fulop, L Molnar, G Barczi, B Merkely Semmelweis University, Budapest, Hungary Critical Care 2007, 11(Suppl 2):P225 (doi: 10.1186/cc5385) Introduction Levosimendan is a new, effective inodilator agent, which is a new alternate drug beside conventional inotropic drugs in treatment of acute and chronic heart failure. Positive inotropic effects of levosimendan is based on myocardial Ca-sensitising. Few clinical data are available about the occurrence of proarrhythmic effects of levosimendan, particularly administered in parallel with catecholamines. Method From PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/20738431 1 January 2006 till 30 July, 41 levosimendantreated patients’ information have been processed in our retrospective study. Indication of levosimendan therapy was acute heart failure on account of myocardial infarction in 23 instances and acute progression of chronic heart failure (NYHA III V) in 18 instances. Right after a 10-minute bolus levosimendan infusion was administered at rate of 0.1 /kg/min for six hours and 24 hours in every single group, respectively. We investigated the occurrence of sustained ventricular or supraventricular arrhythmias for the first 48 hours from the starting of infusion. Results The ratio of hypertension, diabetes, earlier myocardial infarction and ACBG were 58 , 27 , 32 and 15 , respectively, within the monitored population (13 females, 28 males; mean age: 68 years). Three ventricular arrhythmias and 1 supraventricular arrhythmia have been observed during the 48-hour MedChemExpress Veledimex (racemate) period, all of them occurred in acute heart failure sufferers with acute myocardial infarction. Parallel usage of catecholamines (noradrenalin and/or dopamine) and levosimendan therapy was observed in 3 instances, in certainly one of them ventricular tachycardia was observed three hours following starting levosimendan infusion. No arrhythmia was observed in chronic heart failure individuals. The incidence of proarrhythmic effects in the course of levosimendan therapy was 9.75 from the entire.